Nu Skin Appoints New CFO, Grants Stock and Bonus

TL;DR

NU SKIN just hired a new CFO, Jason Wight, with a sweet deal: $475k salary, bonus, 150k stock, and a $500k signing bonus.

AI Summary

Nu Skin Enterprises, Inc. announced on June 5, 2024, the appointment of Jason Wight as Chief Financial Officer, effective June 10, 2024. He will receive an annual base salary of $475,000 and a target annual bonus of 75% of his base salary. Wight will also be granted 150,000 restricted stock units, vesting over three years, and a $500,000 signing bonus.

Why It Matters

The appointment of a new CFO and the associated compensation package can signal the company's financial strategy and outlook to investors.

Risk Assessment

Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategies and performance.

Key Numbers

• $475,000 — CFO Base Salary (Annual compensation for new CFO Jason Wight.)
• 150,000 — RSUs Granted (Stock incentive for new CFO Jason Wight.)
• $500,000 — Signing Bonus (One-time payment to new CFO Jason Wight.)

Key Players & Entities

• Nu Skin Enterprises, Inc. (company) — Registrant
• Jason Wight (person) — Newly appointed Chief Financial Officer
• $475,000 (dollar_amount) — Annual base salary for Jason Wight
• 75% (dollar_amount) — Target annual bonus percentage for Jason Wight
• 150,000 (dollar_amount) — Restricted stock units granted to Jason Wight
• $500,000 (dollar_amount) — Signing bonus for Jason Wight
• June 10, 2024 (date) — Effective date of Jason Wight's appointment

FAQ

Filing Documents

• ef20030699_8k.htm (8-K) — 52KB
• ef20030699_ex10-1.htm (EX-10.1) — 118KB
• 0001140361-24-029122.txt ( ) — 335KB
• nus-20240605.xsd (EX-101.SCH) — 4KB
• nus-20240605_lab.xml (EX-101.LAB) — 21KB
• nus-20240605_pre.xml (EX-101.PRE) — 16KB
• ef20030699_8k_htm.xml (XML) — 4KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On June 5, 2024, at the Nu Skin Enterprises, Inc. (the "Company") 2024 Annual Meeting of Stockholders (the "Annual Meeting"), the Company's stockholders adopted and approved the Company's 2024 Omnibus Incentive Plan (the "2024 Plan"), which previously had been approved by the Company's Board of Directors (the "Board") and Compensation and Human Capital Committee (the "Committee") subject to stockholder approval. The 2024 Plan supersedes the Company's 2010 Omnibus Incentive Plan and its amendments (the "Prior Plan") and is administered by the Committee. Under the 2024 Plan, the following award types may be issued to the Company's employees, non-employee Board members and consultants: options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other share-based awards, performance awards, or any other right, interest or option relating to shares or other property (including cash) granted pursuant to the provisions of the 2024 Plan. The aggregate number of shares of the Company's common stock that may be issued or transferred pursuant to awards under the 2024 Plan is equal to 1,219,919 shares plus the number of shares available for issuance under the Prior Plan as of the date on which the Company's stockholders approved the 2024 Plan, subject to further adjustment under the 2024 Plan's share-counting rules. The 2024 Plan will expire on June 5, 2034 unless earlier terminated by the Committee. The above description of the 2024 Plan is qualified in its entirety by reference to the full text of the 2024 Plan, which is included as Exhibit 10.1 to this report. A more detailed summary of the 2024 Plan can be found in the Company's proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission on April 12, 2024.

07

Item 5.07 Submission of Matters to a Vote of Security Holders. The Company's stockholders approved the following proposals at the Annual Meeting on June 5, 2024: Election of eight directors to serve until their successors are duly elected and qualified at the next annual meeting of stockholders or until their earlier death, resignation or removal; Advisory approval of the Company's executive compensation; Approval of the Company's 2024 Omnibus Incentive Plan; and Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2024. The voting results were as follows: For Against Abstain Broker Non-Votes Election of Directors Emma S. Battle 37,870,290 532,410 30,791 4,005,546 Daniel W. Campbell 36,903,538 1,499,772 30,181 4,005,546 Steven J. Lund 36,778,592 1,630,986 23,913 4,005,546 Ryan S. Napierski 37,308,512 1,101,115 23,864 4,005,546 Laura Nathanson 37,792,955 610,575 29,961 4,005,546 Thomas R. Pisano 35,340,571 3,062,694 30,226 4,005,546 Zheqing (Simon) Shen 38,073,457 329,951 30,083 4,005,546 Edwina D. Woodbury 38,069,325 334,854 29,312 4,005,546 For Against Abstain Broker Non-Votes Advisory Approval of the Company's Executive Compensation 36,992,257 1,415,374 25,860 4,005,546 Approval of the 2024 Omnibus Incentive Plan 35,854,226 2,561,619 17,646 4,005,546 Ratification of PricewaterhouseCoopers LLP 41,569,751 828,355 40,931 0

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. 10.1 Nu Skin Enterprises, Inc. 2024 Omnibus Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NU SKIN ENTERPRISES, INC. (Registrant) /s/ James D. Thomas James D. Thomas Chief Financial Officer Date: June 6, 2024

View Full Filing

View this 8-K filing on SEC EDGAR